Skip to content
10-Q

Quarterly Report

ALSERES PHARMACEUTICALS INC /DE

0001193125-12-350936

← back to feed
Filed
Aug 13, 2012 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2012 · Jul 31, 2012 30.64M sh
Stock Repurchased Q2 2012 · Jun 30, 2012 $26.36K
Capex Q2 2012 · Jun 30, 2012 $1.65M
Operating Cash Flow Q2 2012 · Jun 30, 2012 −$159.96M
Operating Cash Flow Q2 2012 · Jun 30, 2011 −$1.55M
Short Term Investments Q2 2012 · Jun 30, 2012 $20.39K
Short Term Investments Q2 2012 · Dec 31, 2011 $27.45K
Stockholders Equity Q2 2012 · Jun 30, 2012 −$31.23M
Stockholders Equity Q2 2012 · Dec 31, 2011 −$30.6M
Current Liabilities Q2 2012 · Jun 30, 2012 $31M
Current Liabilities Q2 2012 · Dec 31, 2011 $30.42M
Total Liabilities Q2 2012 · Jun 30, 2012 $31M
Total Liabilities Q2 2012 · Dec 31, 2011 $30.42M
Current Assets Q2 2012 · Jun 30, 2012 $127.95K
Current Assets Q2 2012 · Dec 31, 2011 $168.25K
Total Assets Q2 2012 · Jun 30, 2012 $129.53K
Total Assets Q2 2012 · Dec 31, 2011 $170.73K
Sga Expense Q2 2012 · Jun 30, 2012 $69.68M
Sga Expense Q2 2012 · Jun 30, 2011 $571.28K
Sga Expense Q2 2012 · Jun 30, 2011 $1.17M
Net Income Q2 2012 · Jun 30, 2012 −$197.66M
Net Income Q2 2012 · Jun 30, 2011 −$533.54K
Net Income Q2 2012 · Jun 30, 2011 −$1.61M
Operating Income Q2 2012 · Jun 30, 2012 −$195.95M
Operating Income restated Q2 2012 · Jun 30, 2011 −$68.44K
Operating Income restated Q2 2012 · Jun 30, 2011 −$691.64K
Revenue Q2 2012 · Jun 30, 2012 $1.4M
Cash And Equivalents Q2 2012 · Jun 30, 2011 $73.66K
Cash And Equivalents Q2 2012 · Dec 31, 2010 $98.51K